(2023.6.3)
About DF1001
DF1001 is an investigational first-in-class immune engaging drug candidate targeting HER2 that drives immune activation in solid tumors. DF1001 stimulates co-activating NK receptors, where NKG2D and CD16 co-stimulation yields distinctive and potent NK cell, γδ T cell, and CD8+ T cell activation. DF1001 is being evaluated in adult patients for the treatment of advanced solid HER2-positive tumors. DF1001 was discovered and developed using Dragonfly's TriNKET Platform. DF1001 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF1001 is the most advanced in a pipeline of TriNKETs that Dragonfly is developing to address high unmet needs for patients across a broad range of disease areas.
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing therapies that use its novel bispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly-owned clinical assets and multiple assets in the clinic with partners, Dragonfly has a deep pipeline of wholly-owned preclinical candidates developed using its proprietary platforms as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meetin
/PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its...
www.prnewswire.com
"Dragonfly Therapeutics, Inc...today announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly's TriNKET technology platform and Dragonfly's lead clinical asset, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate (ADC), in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC)....Dragonfly will have operational control of the study and first patients are expected to receive this combination in Q2 2024. Clinical trial sites are currently open in the U.S., France, Belgium, Denmark and the Netherlands. Additional sites in North America, Europe and Asia Pacific will open in 2024."
https://clin.larvol.com/trial-detail/NCT04143711
Study of DF1001 in Patients with Advanced Solid Tumors
clin.larvol.com
'신약개발 소식, 해외 논문들' 카테고리의 다른 글
| ORIC-114 (0) | 2025.02.07 |
|---|---|
| 신약 이름 정리 (0) | 2025.02.07 |
| ‘자연살해세포-세툭시맙’ 병용요법, 폐암 치료 안전성 및 효과성 확인 (0) | 2025.02.06 |
| 암세포를 정상세포로…韓 암치료 신기술 개발 (1) | 2024.12.28 |
| 96% 높은 정확도로 암 유전자 `콕`…암 조기 진단 재발 모니터링 활용 (1) | 2024.11.13 |